Skip to main content
OpenTrials
Completed

NCT Number: NCT07355530

Can Adipose Derived Regenrative Cells be Used for Treating Erectile Dysfunction After Radical Prostatectomy

The goal of this study was to investigate if adipose derived regenerative cells can be used as a treatment for erectile dysfunction following radical prostatectomy.

70 participants were enrolled in the study and was performed as a double- blinded study. 35 participants in the active study arm recieved an injection into the penis of adipose derived regenerative cells, while the participants of the placebo arm recieved a placebo injection.

All 70 participants undervent liposuccion of the abdomen to harvest the adipose derived regenerative cells, and the 35 participants in the active study arm recieved their own regenerative cells.

All participants answered the questionnaires International-Index-of- Erectile function 5 and Erection Hardness Scale before treatment and after 1,3,6 and 12 months. These data was used to evaluate the effect of one injection of adipose derived regenerative cells.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

ED Adipose Derived Stem Cells

Sex eligibility

Male

Study type

Interventional

Phase

Phase 2

Primary location

Odense Universityhospital

Odense, 5000, Denmark

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Nervesparing robot assisted RP
  • Erectile dysfunction for more than a year after RP
  • Normal erectile function before RP (IIEF-5 > 22) and postoperative IIEF-5 score 5-20 or EHS 1
  • Involved in a monogamous, heterosexual relationship (since questionnaires are only valid for heterosexual relationsships), where both parts are interested in sexual activities
  • Insufficient effect of standard medical treatment for ED
  • Subcutaneous adipose deposits on the abdomen > 120 mL
  • Performance status 0
  • Ability to give informed consent
  • Proficiency in the Danish language to understand the questionnaires IIEF-5 and EHS

Exclusion criteria

  • Problems with general anesthesia
  • Incontinence after RP
  • Anti-thrombotic treatment that cannot be discontinued or substituted with heparin
  • No interest in sexual interaction with a partner
  • Previous pelvic surgery or radiation
  • Systemic autoimmune disease
  • Alcohol or drug abuse

Treatment and study plan

Adipose-Derived Regenerative Cells

Drug

Adipose-derived regenerative cells was injected into the corpus cavernosum.

Placebo

Other

Injection of ringer lactate

Primary outcomes

  1. Changes in International-Index-of-Erectile-Function 5 12 months after intervention

    Time frame: 12 months

    All paticipants answered the questionnaire International-Index-of-Erectile-Function 5 at baseline and after 12 months.

    The questionnaire focus on confidence, erection hardness, maintaining erection and satisfaction during intercourse.

    The scale of the score is from 5 to 25. The higher the score is, the better is the erectile function.

    A score from 5-7 means severe erectile dysfunction A score from 8-11 is moderate erectile dysfunction A score from 12-16 is mild to moderate erectile dysfunction A score from 17-21 is mild erectile dysfunction A score from respresents no erectile dysfunction. A higher score after 12 months means that the erectile function is improved.

Secondary outcomes

  1. Changes in Erectile Hardness Scale (EHS) six months after intervention

    Time frame: 6 months

    Erectile Hardness Scale (EHS) was answered at baseline and 6 months after intervention. The scale are running from 0-4, it is used to rate erection firmness for penetration.

    0: no enlargement at all

    • Enlarged but not firm
    • Firm, but not hard enough for penetration
    • Hard enough for penetration, but not fully rigid
    • fully rigid and completely hard. A higher score after 6 month means that the erection is better than before intervention.

  2. RigiScan

    Time frame: 6 months

    Changes in RigiScan scores 6 months after intervention. RigiScan is a non- invasive diagnostic devise that are used to measure penile rigidity and circumference changes during sleep. The divice consist of two loops and a monitor, and the loops are able to monitor the erection quality over time, if the values of the data improve 6 months after intervention, is the erection improved.

    We monitored Frequency of erections during sleep (number of erections)

  3. RigiScan data

    Time frame: 6 months

    Changes in RigiScan scores 6 months after intervention. RigiScan is a non- invasive diagnostic devise that are used to measure penile rigidity and circumference changes during sleep. The divice consist of two loops and a monitor, and the loops are able to monitor the erection quality over time, if the values of the data improve 6 months after intervention, is the erection improved.

    We monitored duration of erection during sleep in minutes.

  4. RigiScan data

    Time frame: 6 months

    Changes in RigiScan scores 6 months after intervention. RigiScan is a non- invasive diagnostic devise that are used to measure penile rigidity and circumference changes during sleep. The divice consist of two loops and a monitor, and the loops are able to monitor the erection quality over time, if the values of the data improve 6 months after intervention, is the erection improved.

    We monitored tumescence of erection, the expansion of the circumference in cm.

  5. RigiScan data

    Time frame: 6 months

    Changes in RigiScan scores 6 months after intervention. RigiScan is a non- invasive diagnostic devise that are used to measure penile rigidity and circumference changes during sleep. The divice consist of two loops and a monitor, and the loops are able to monitor the erection quality over time, if the values of the data improve 6 months after intervention, is the erection improved.

    We monitored hardness of erection in %

Sponsors and collaborators

Lead sponsor

Odense University Hospital

Other

Collaborators

  • University of Southern Denmark

Registry information

Official study title

A Randomized Double-blind, Placebo-controlled Trial of Adipose-derived Regenerative Cells Injected Into Corpora Cavernosum Following Radical Prostatectomy

Important dates

Study start
2018
Primary completion
2021
Study completion
2021
First posted
Jan 21, 2026
Registry last updated
Jan 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.